Literature DB >> 30627300

ESTIMATING AND COMPARING CANCER PROGRESSION RISKS UNDER VARYING SURVEILLANCE PROTOCOLS.

Jane M Lange1, Roman Gulati1, Amy S Leonardson1, Daniel W Lin2, Lisa F Newcomb1, Bruce J Trock3, H Ballentine Carter3, Matthew R Cooperberg4, Janet E Cowan4, Lawrence H Klotz5, Ruth Etzioni1,2.   

Abstract

Outcomes after cancer diagnosis and treatment are often observed at discrete times via doctor-patient encounters or specialized diagnostic examinations. Despite their ubiquity as endpoints in cancer studies, such outcomes pose challenges for analysis. In particular, comparisons between studies or patient populations with different surveillance schema may be confounded by differences in visit frequencies. We present a statistical framework based on multistate and hidden Markov models that represents events on a continuous time scale given data with discrete observation times. To demonstrate this framework, we consider the problem of comparing risks of prostate cancer progression across multiple active surveillance cohorts with different surveillance frequencies. We show that the different surveillance schedules partially explain observed differences in the progression risks between cohorts. Our application permits the conclusion that differences in underlying cancer progression risks across cohorts persist after accounting for different surveillance frequencies.

Entities:  

Year:  2018        PMID: 30627300      PMCID: PMC6322848          DOI: 10.1214/17-AOAS1130

Source DB:  PubMed          Journal:  Ann Appl Stat        ISSN: 1932-6157            Impact factor:   2.083


  4 in total

1.  Prostate cancer mortality and metastasis under different biopsy frequencies in North American active surveillance cohorts.

Authors:  Jane M Lange; Aaron A Laviana; David F Penson; Daniel W Lin; Anna Bill-Axelson; Sigrid V Carlsson; Lisa F Newcomb; Bruce J Trock; H Ballentine Carter; Peter R Carroll; Mathew R Cooperberg; Janet E Cowan; Laurence H Klotz; Ruth B Etzioni
Journal:  Cancer       Date:  2019-10-22       Impact factor: 6.860

Review 2.  [Active surveillance in prostate cancer].

Authors:  E Erne; S Kaufmann; K Nikolaou; A Stenzl; J Bedke
Journal:  Urologe A       Date:  2019-05       Impact factor: 0.639

3.  Multistate models for the natural history of cancer progression.

Authors:  Li C Cheung; Paul S Albert; Shrutikona Das; Richard J Cook
Journal:  Br J Cancer       Date:  2022-07-11       Impact factor: 9.075

4.  Bayesian inference for continuous-time hidden Markov models with an unknown number of states.

Authors:  Yu Luo; David A Stephens
Journal:  Stat Comput       Date:  2021-08-10       Impact factor: 2.559

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.